In humans, myo-Ins has been shown to potentially reduce the symptoms of metabolic syndrome, including insulin resistance and dyslipidemia (Croze and Soulage, 2013), as well as affect other endocrine disorders such as polycystic ovary syndrome (Unfer et al., 2012), all of which relate to its role as an insulin mimetic. This evidence concerns the gene INS and polycystic ovary syndrome.